These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2016-002576-27||Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter pha...||not-yet-due|
|Ongoing||2018-002231-24||A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to...||not-yet-due|
|Ongoing||2018-003346-17||Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2||not-yet-due|
|Exempt||2018-003541-42||Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial - FOLFIRINOX-R||not-yet-due|
|Ongoing||2019-001515-23||Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma Etu...||not-yet-due|
|Ongoing||2019-002971-32||A Double blind randomized phase III study of pravastatin vs placebo as primary prevention of severe subcutaneous breast fibrosis in hyper-radiosensitive identified patients with breast cancer Etude...||not-yet-due|
|Ongoing||2019-003357-29||Intensive intraperitoneal therapy in advanced ovarian cancer combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and postoperative intraperitoneal chemotherapy (IPC)...||not-yet-due|
|Ongoing||2020-002517-18||Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with loc...||not-yet-due|